Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20388835 | 0.81 | TRPV1 (0.48) | TRPV1TRPA1SPHK1 | |
| SCHEMBL16538717 | 0.79 | TRPV1 (0.33) | TRPV1TRPA1GABBR2GABBR1SPHK1 | |
| SCHEMBL15604477 | 0.79 | SPHK1 (0.38) | TRPV1TRPA1SPHK1 | |
| SCHEMBL8745700 | 0.78 | — | — | |
| SCHEMBL18820262 | 0.78 | — | — | |
| SCHEMBL725910 | 0.77 | — | — | |
| SCHEMBL24022315 | 0.77 | METAP1 (0.41) | TRPV1TRPA1GABRR1GABBR2GABBR1 | |
| Fluoride SCHEMBL28418823 | 0.76 | TRPV1 (0.40) | TRPV1TRPA1GABRR1GABBR2GABBR1 | |
| SCHEMBL24630104 | 0.76 | GABRR1 (0.39) | TRPV1TRPA1GABRR1GABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL11197477 | 0.76 | TRPV1 (0.40) | TRPV1TRPA1GABRR1GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | CHIA, MMP8, CHIT1 | TRPV1 1002/4885TRPA1 1546/4885GABRR1 3639/4885 |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | CHIT1, ALG1, CSGALNACT1 | TRPV1 1889/4885TRPA1 1671/4885GABRR1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.